Mounjaro Safety Guide

Mounjaro side effects: what the data actually shows

By Iacob Pastina · Independent Researcher & Publisher · Updated October 7, 2026

Important: Mounjaro is FDA-approved for type 2 diabetes

Mounjaro (tirzepatide) is approved by the FDA to treat type 2 diabetes. It is not FDA-approved for weight loss. The same active molecule (tirzepatide) is also marketed under the brand name Zepbound, which IS FDA-approved for chronic weight management.

The common-side-effect table below reports 5 mg, 10 mg and 15 mg groups from two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 and SURPASS-5). It does not give rates for every dose or population. For the weight-management product, see the Zepbound side effects deep dive.

The most common Mounjaro side effects at diabetes doses are gastrointestinal: nausea (12% at 5mg / 15% at 10mg / 18% at 15mg), diarrhea (12-17%), decreased appetite (5-11%), and vomiting (5-9%) in the cited adult placebo-controlled trials. These percentages do not predict your symptoms or when they will occur. Mounjaro is a dual GIP/GLP-1 receptor agonist. The trial percentages below come from the FDA-approved Mounjaro prescribing information.

Call your doctor or 911 immediately if you experience:

  • • Severe abdominal pain that does not go away, with or without vomiting (stop Mounjaro and contact a clinician immediately; pain may reach your back)
  • • Severe hypoglycemia: confusion, loss of consciousness, seizure (call 911 if unconscious)
  • • Difficulty breathing, throat swelling, or widespread hives (call 911)
  • • Sudden vision changes, blurred or distorted vision, especially with pre-existing retinopathy (provider call same day)
  • • Ongoing vomiting or diarrhea, trouble keeping fluids down, or markedly reduced urination (contact your clinician promptly; do not wait for a fixed number of hours)
  • • Sharp upper-right pain after fatty meals with fever or jaundice (gallbladder, provider call)

Report any serious adverse event to FDA MedWatch.

Common side effects: rates from the Mounjaro label

Source: section 6.1, Table 1 of the FDA-approved Mounjaro prescribing information. These 5 mg, 10 mg and 15 mg rates pool two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 and SURPASS-5). Each percentage counts people who reported the symptom at least once; it does not describe its severity or duration.

Side effect5mg10mg15mg
Nausea12%15%18%
Diarrhea12%13%17%
Decreased appetite5%10%11%
Constipation6%6%7%
Dyspepsia (indigestion)8%8%5%
Vomiting5%5%9%
Abdominal pain6%5%5%

How do dose changes affect symptoms?

Reported nausea, vomiting and diarrhea can occur during dose increases. Trial percentages do not tell you which week a symptom will start or stop. Follow your prescriber's instructions for your exact product and indication, and contact them about troublesome symptoms before changing your dose.

The Mounjaro prescribing information, section 2 explains the dosing instructions. It is a reference for your clinician, not a schedule to advance through automatically.

What should you ask your prescriber about side effects?

Use the Mounjaro prescribing information and Medication Guide alongside this checklist. For help recording symptoms and preparing questions, see our symptom-management guide.

FDA's January 2026 review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines. Mood changes still deserve care: tell your clinician about new or worsening depression or suicidal thoughts. Call or text 988 for crisis support; call 911 for immediate danger.

Serious side effects, recognize these red flags

These warning signs need prompt attention. The Mounjaro label calls for monitoring people with a history of diabetic retinopathy; ask your clinician what monitoring you need.

Pancreatitis

Reported in clinical trials; requires urgent assessment

Red-flag symptoms: Severe or persistent abdominal pain that may reach your back, with or without nausea or vomiting

Action: STOP Mounjaro and seek emergency care immediately. Do not restart without provider clearance.

Diabetic retinopathy complications

Label warning: monitor people with a history of diabetic retinopathy

Red-flag symptoms: New or worsening blurred vision, especially in patients with pre-existing diabetic retinopathy. Rapid improvement in blood glucose can transiently worsen retinopathy in vulnerable patients.

Action: Tell your clinician about any history of diabetic retinopathy and any vision changes. Ask what eye monitoring is appropriate for you.

Gallbladder problems

Acute gallbladder disease: 0.6% vs 0% on placebo in adult placebo-controlled trials

Red-flag symptoms: Sharp upper-right abdominal pain after fatty meals, fever, jaundice. Rapid weight changes, even at diabetes doses, can precipitate gallstones.

Action: Contact your clinician promptly for these symptoms. They can assess whether gallbladder tests and follow-up are needed.

Acute kidney injury

Reported, including after fluid loss from vomiting or diarrhea

Red-flag symptoms: Decreased urine output, swelling, fatigue, usually after persistent vomiting or diarrhea causing dehydration

Action: Contact your clinician promptly for ongoing vomiting or diarrhea, trouble keeping fluids down, or signs of dehydration. Do not wait for a fixed number of hours.

Severe hypoglycemia

Variable, primarily in patients on insulin or sulfonylureas

Red-flag symptoms: Confusion, loss of consciousness, seizure, severe shakiness with sweating

Action: Follow the low-blood-sugar plan agreed with your clinician. If someone is unconscious, having a seizure, or cannot safely swallow, call 911 and do not give food or drink by mouth. Discuss insulin or sulfonylurea adjustments with your prescriber.

Severe allergic reaction (anaphylaxis)

Reported; can be life-threatening

Red-flag symptoms: Difficulty breathing, throat or facial swelling, widespread hives, drop in blood pressure

Action: CALL 911. Do not drive yourself.

The boxed warning: thyroid C-cell tumors

Mounjaro carries a boxed warning for thyroid C-cell tumors. This is based on rodent studies; no causal link has been established in humans.

Mounjaro is contraindicated in patients with:

  • • Personal or family history of medullary thyroid carcinoma (MTC)
  • • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Your prescriber should screen for these before initiating Mounjaro. If a telehealth provider does not ask about thyroid history during intake, treat that as a quality flag.

Choosing a provider for Mounjaro

Because Mounjaro is an FDA-approved diabetes medication, the prescribing bar is different from weight-loss-only programs.

You want a provider who:

  1. Reviews your diabetes history, including any retinopathy
  2. Reviews insulin, sulfonylureas and other medicines with you
  3. Explains your individual glucose-monitoring and follow-up plan
  4. Gives you a plan for low blood sugar and urgent symptoms

Confirm whether a service manages type 2 diabetes, how it coordinates with your existing clinician, and who handles questions between visits.

Compare each program's current clinical-oversight evidence in our full rankings. Overall scores are not a medical-safety endorsement. Ask your existing diabetes clinician about continuity of care before changing services. Our Sprout Health review is a starting point for program research, not a recommendation for managing your symptoms.

Explore program costs and recorded support options in the program finder, or take the 60-second match quiz to find providers that fit your support needs.

Related

Sources

This page is for informational purposes only and is not medical advice. Always discuss medication decisions with a licensed prescriber. Mounjaro is FDA-approved for type 2 diabetes mellitus in adults. Side-effect rates are population averages from clinical trials and may not reflect your individual experience. If you are experiencing a medical emergency, call 911.